NCT04469764View on ClinicalTrials.gov

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2027

Conditions
Recurrent Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
DRUG

Abemaciclib

Given PO

DRUG

Anastrozole

Given PO

DRUG

Letrozole

Given PO

Trial Locations (1)

90095

RECRUITING

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

Jonsson Comprehensive Cancer Center

OTHER